RightRep EN · PT Open the app
BLOG

Does Exercise Help Hypothyroidism? The Thyroid Audit: What Training Actually Does for the Underactive Gland (the Pill-Fixes-the-Blood-Not-the-Person File Where 1.5% of a County Sits on Levothyroxine and Scores Worse on the Questionnaire Anyway at Normal TSH, the Epidemiology File Where Iodine and Ageing Decide Risk and the Commonest Thyroid Dysfunction Belongs to Women, the Honest Core of the 2023 Meta Where TSH Sat Flat at −0.96 While Physical and Mental Health Improved, the 2026 Upset Where Levothyroxine Plus Aerobic Plus Resistance Became the Preferred Strategy at TSH −3.97 High Certainty While Liothyronine Priced Adverse Events at RR 15.54, the 4-Arm RCT Where Combined Training Won TSH and Mental Health and Aerobic Won VO₂max, the Brazilian File Where a 12-Point Functional-Capacity Deficit Fell to 16 Weeks of Bike and Treadmill, the Kinetics File Where Heart-Rate On-Kinetics Sped from 39.6 to 28.9 Seconds, the Population Null Where TSH Doesn't Even Predict Who Moves, and the Treatment Landscape Where Exercise Is the Add-On with the Best Safety Profile)

By RightRep AI Assistant · · 18 min read

The levothyroxine script in the gym bag is its own subculture: the lifter who is always cold, gains weight on a spreadsheet-perfect diet, sleeps nine hours and wakes tired, and has heard both folklores — "cardio will fix your thyroid" from one corner and "your metabolism is broken, why bother" from the other. Hypothyroidism is the commonest thyroid dysfunction and one of the commonest endocrine conditions in any gym population [1], yet this library has audited what training does for PCOS, menopause, the period and even whether to train sick — never the thyroid itself. Does exercise help hypothyroidism — can you train with it, does training move the gland or only the person, and where does it sit next to the pill?

The evidence answers with one honest split and nine files, and the split organizes all of them. The pill normalizes the blood but not always the person: a substantial proportion of patients who reach biochemical treatment targets keep their complaints [2], and the founding community study measured it — 1.5% of a 63,000-person county on levothyroxine, scoring worse on psychological well-being than matched controls even with a normal TSH [3]. Training is the add-on that moves what the pill leaves behind: the 2023 meta-analysis found exercise improves physical and mental health outcomes in hypothyroidism while TSH sits statistically flat (Hedges' g −0.96, 95% CI −2.71 to 0.79, p = 0.160) [4]; the 2026 network meta-analysis then crowned the combination — levothyroxine + aerobic + resistance training as the preferred add-on strategy, TSH SMD −3.97 at high certainty, quality of life +1.62, mental health +2.1, while the pharmacological darling liothyronine carried adverse events at RR 15.54 [5]. The flagship RCT splits the modalities (combined training wins TSH and mental health, aerobic wins VO₂max [7]), the Brazilian file supplies the deficit number training targets (functional capacity 77.0 vs 88.8 in euthyroid women) and its 16-week repair [8], and the honesty files travel with them: the population cohort where TSH does not even predict who moves [10], and the counterfile — exercise is not a replacement for levothyroxine [2][4]. Every number below comes from an abstract that was read directly and checked against its claim.

The short answer: yes for the person, mostly no for the gland

Strip the folklores and here is what the literature holds. Hypothyroidism — fatigue, lethargy, cold intolerance, weight gain as the classic symptom cluster [2] — is treated with levothyroxine, and the treatment works at what it targets: the blood column normalizes [2]. What it leaves is the person column: persistent complaints in a substantial proportion of biochemically controlled patients [2], measurable as worse GHQ-12 and thyroid-symptom questionnaire scores at normal TSH [3] and confirmed across 17 studies of long-term treated patients [6]. Exercise is precisely the reverse instrument. It is safe in hypothyroidism and improves the physical and mental health outcomes the pill leaves behind [4], the 2026 network meta-analysis makes levothyroxine + aerobic + resistance the preferred add-on combination [5], and the 4-arm RCT shows every modality — aerobic, resistance, combined — improving TSH, T4, lipids, fitness and quality of life versus control over 12 weeks [7]. But the honest core holds: pooled TSH does not significantly move under training in the pairwise meta [4], the evidence base is small and mostly subclinical women [4], and no file in this audit supports training instead of the pill [2][4]. Take the levothyroxine; train anyway — the questionnaire improves even when the TSH column doesn't.

The condition file: the commonest thyroid dysfunction, and it belongs to women

The epidemiology first. The global review is blunt about the levers: iodine nutrition is a key determinant of thyroid disease risk, with ageing among the other influences — and hypothyroidism is the commonest thyroid dysfunction, more prevalent than its hyper counterpart across populations [1]. The Lancet seminar draws the clinical frame: hypothyroidism is thyroid hormone deficiency, "readily diagnosed and managed but potentially fatal in severe cases if untreated," with the most common adult symptoms being fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice and dry skin — a presentation that differs with age and sex — and standard treatment being levothyroxine replacement [2]. In iodine-replete countries the commonest cause is autoimmune thyroiditis — Hashimoto's — and the 22-million-person UK cohort documents the autoimmune clustering: autoimmune disorders co-occur over time and by age and sex far beyond chance, thyroid disease sitting at the centre of that web [12]. The gym-facing translation is the pt-BR one too: women dominate this condition as they do PCOS and the menopause transition, autoimmune thyroid disease is highly prevalent in Brazil, and the woman on levothyroxine asking whether she can still build a training life is the modal patient of this file [1][12].

The residual-symptom file: the founding number

The number that justifies this entire audit was measured in 2002. Computerized prescribing records from five UK general practices identified 961 patients on thyroxine for at least four months inside a population of 63,000 — 1.5% of the county — each matched to age- and sex-matched controls, all sent the GHQ-12 (minor psychiatric morbidity) and a 12-question thyroid symptom questionnaire [3]. The result that has structured two decades of research: patients scored worse than controls on both instruments — GHQ-12 caseness 32.3% vs 25.6% (P = 0.014) — and the deficit persisted in the subgroup with a normal TSH: caseness 34.4% vs 25.6% (P < 0.005), thyroid symptom questionnaire abnormal in 48.6% vs 35.0% (P < 0.001), differences that survived correction for chronic disease and drug use [3]. The authors' own conclusion: patients on thyroxine replacement "even with a normal TSH display significant impairment in psychological well-being" [3]. The Lancet seminar had already institutionalized the phenomenon — "a substantial proportion of patients who reach biochemical treatment targets have persistent complaints" [2] — and the 2025 systematic review of 17 studies in long-term treated patients confirmed the pattern: mental and physical well-being impaired in 10 studies, social role in 7, with the reviewers flagging design flaws in 13 of the 17 as the caveat that travels with the finding [6]. This is the gap training is auditioning to fill.

The honest core: the 2023 meta-analysis

The founding training verdict is the systematic review and meta-analysis that pooled the field through April 2023: 10 studies, low-to-moderate methodological quality, most performed in women with subclinical hypothyroidism [4]. Its two-column verdict is the spine of this post. Column one, safety and the person: exercise seemed safe, with aerobic and resistance training leading to improvements in outcomes related to physical and mental health [4]. Column two, the gland: pooling 120 participants, TSH showed a non-significant trend towards reduction (Hedges' g −0.96, 95% CI −2.71 to 0.79, p = 0.160; I² = 92%); the between-group analysis with 180 participants stayed non-significant (SMD −1.09, 95% CI −2.88 to 0.70, p = 0.23; I² = 95%); FT3 and FT4 pooled to similar null findings [4]. The reviewers' conclusion, quoted exactly because it is the audit's thesis: "exercise does not have a significant impact on thyroid function, although its practice can lead to secondary outcomes related to physical and mental health" [4]. Note what the wide confidence intervals and 92–95% heterogeneity mean: with small, heterogeneous trials, the pairwise meta cannot rule medium effects in or out — a silence, not a zero. Which is exactly where the next file enters.

The 2026 upset: the network meta-analysis crowns the combination

Three years later the network meta-analysis re-priced the whole add-on market: 35 randomized trials, 3,508 patients, Bayesian pooling, certainty graded with CINeMA [5]. Versus placebo, levothyroxine + aerobic training + resistance training reduced TSH (SMD −3.97, 95% CrI −5.76 to −2.18, CINeMA high certainty); versus levothyroxine alone it improved quality of life (SMD 1.62, 0.78 to 2.46) and mental health (SMD 2.1, 1.19 to 3.01, low certainty), with levothyroxine + resistance alone improving physical function (SMD 1.59, 0.76 to 2.43) [5]. The pharmacological legs of the same table: micronutrient combos moved FT4 and FT3 (LT4 + zinc + magnesium + vitamin A on FT4 at 1.95, high certainty; LT4 + zinc on FT3 at 1.46, low certainty) — and liothyronine (LT3), the drug patients ask for, increased adverse events at RR 15.54 (95% CrI 2.68 to 501.14, very low certainty) [5]. The authors' verdict: "the combination of LT4, AT, and RT may be the preferred strategy for reducing TSH, enhancing QoL, and improving MHS" [5]. The tension with the 2023 meta is real and belongs in the open: Duñabeitia pooled 10 trials pairwise and got a flat TSH at 92–95% heterogeneity [4]; Lv pooled 35 trials with direct and indirect evidence and stamped high certainty on −3.97 [5]. More trials, Bayesian indirect comparison and different trial sets explain most of the gap — but the honest read prices both: the gland might move more than the 2023 meta suggests, and the person-level outcomes are where the evidence has been consistent all along [4][5]. Two honest footnotes: the LT3 harm signal is very-low-certainty and sits against trials where combination therapy was safe and preferred by patients [5][11] — and the exercise legs of the NMA inherit the same small-trial base as [4].

The 4-arm flagship: combined wins the blood and the mind, aerobic wins the lungs

The cleanest single experiment in the file randomized 60 women aged 35–45 with clinical hypothyroidism, all on levothyroxine, into four equal arms — aerobic, resistance, combined aerobic/resistance, or control — training at low-to-moderate intensity three days a week for 12 weeks [7]. Every exercise arm improved TSH, free T4, lipid profile, estimated VO₂max and both SF-12 quality-of-life components versus baseline and control (p < 0.05) [7]. The modality split is the programming takeaway: combined AT/RT beat the single modes on TSH and the mental component of SF-12 (p < 0.05); aerobic won estimated VO₂max (combined second, resistance third); T4, lipids and the physical component were equal across exercise arms [7]. The authors' conclusion reads like a programme: all three modes equally improve T4, lipids and physical quality of life, combined training adds the greatest TSH and mental-health gains, aerobic adds the greatest exercise capacity [7]. The NMA's preferred combination [5] and this RCT's winner arm agree with each other — and with what the general muscle literature already told you about combining modalities.

The Brazilian file: the 12-point deficit and its 16-week repair

The pt-BR spine of this audit is the Brazilian randomized trial that first measured what subclinical hypothyroidism takes, then trained it. Phase one, cross-sectional: 22 women with subclinical hypothyroidism scored functional capacity 77.0 ± 23.0 on SF-36 versus 88.8 ± 14.6 in 33 euthyroid women (p = 0.020) — a twelve-point deficit on the domain that answers "can you do your life" [8]. Phase two, the randomized trial: women with subclinical hypothyroidism split into trained (n = 10) and sedentary (n = 10) groups, the trained group doing 60 minutes of bike and treadmill work three times a week for 16 weeks — after which functional capacity, general health, emotional aspects and both mental and physical components of quality of life improved, while the sedentary group showed no significant changes [8]. The n = 20 honesty tag travels with the finding — this is a small trial — but its direction matches the Egyptian 4-arm trial [7], the meta [4] and the NMA [5]: the questionnaire is the outcome training reliably moves. For the Lusophone reader asking pode treinar com hipotireoidismo, this is the domestic evidence that the answer is yes — measurably.

The kinetics file: the cardiovascular sluggishness is trainable

One level below the questionnaire sits the machinery the fatigue runs on, and the same Brazilian group measured it. Eighteen women with subclinical hypothyroidism were randomized to trained or control groups; heart-rate on-kinetics were extracted during cycle-ergometer tests as the mean response time — the seconds the cardiovascular system takes to reach 63% of its steady-state heart rate [9]. Twelve weeks of endurance training (50 minutes, three times a week, 70–85% of age-predicted max heart rate) produced: MRT 39.6 ± 10.0 → 28.9 ± 8.4 seconds in the trained group versus 53.6 ± 20.3 → 55.0 ± 19.7 in controls (p = 0.001), with physical-activity level rising in parallel (p = 0.005) [9]. Read that as the mechanistic bridge of the file: the sluggish cardio-acceleration that makes hypothyroid patients describe stairs as walls is not fixed by the gland's number — it responds to twelve weeks of the right stimulus, which is precisely the adaptation a tracked programme makes visible week by week.

The population null: TSH doesn't even decide who moves

The honesty file that keeps this audit from becoming a miracle claim. The Rotterdam cohort asked the reverse question — does the gland determine activity? 2,470 participants cross-sectionally, 1,907 longitudinally over ~5 years: no association between TSH (β = 0.65, 95% CI −1.67 to 2.98) or free T4 (β = 2.76, −7.15 to 12.66) and total physical activity, in either direction of analysis [10]. The gland's number does not predestine deconditioning — which cuts both ways and usefully: the hypothyroid patient is not condemned to inactivity by biology, and the deconditioning that accompanies the untreated condition is substantially behavioural, therefore trainable [10]. It also disciplines the mechanism story: training's benefits in this file arrive through fitness, muscle, mood and cardiovascular adaptation [4][7][8][9] — not through repeatedly shocking a sluggish gland into overdrive.

The treatment landscape: where exercise sits in the pharmacy

The 2024 review of emerging therapies maps the frontier patients actually hear about: a minority of patients remain symptomatic despite normalized TSH, combination levothyroxine–liothyronine trials report safety and patient preference with quality-of-life and cognition gains in some who switch, slow-release T3 formulations are in testing, transplanted human thyroid organoids have restored euthyroidism in mice, and the field now recognizes tissue-specific thyroid-hormone resistance — liver-selective T3-like molecules already in trials for fatty liver disease [11]. Price exercise inside that pharmacy: it is the add-on whose benefit column (quality of life, mental health, physical function [5], fitness [7], functional capacity [8], cardiovascular kinetics [9]) is the same column the drug pipeline chases — with a safety profile no investigational molecule will beat and a price no pharmacy will match [4][5]. It does not replace levothyroxine any more than it replaces diagnosis [2][4]; it competes for the residual symptom market, where the evidence says it wins.

What to actually do with this file

  • Treat first, train second. Overt hypothyroidism must be diagnosed and biochemically controlled before performance is programmed [2][4]. The training question starts on top of a stable levothyroxine dose — never instead of it.
  • Combine aerobic and resistance. The NMA's preferred strategy is levothyroxine + aerobic + resistance [5]; the 4-arm RCT's combined arm won TSH and mental health while every mode moved lipids, T4 and quality of life [7]. This is the standard two-modality programme with a thyroid-specific reason.
  • Start low-to-moderate and let the kinetics come. Both training trials used low-to-moderate intensity, three days a week [7][8]; twelve to sixteen weeks is the window where the questionnaires and the heart-rate kinetics moved [8][9]. Fatigue is the presenting symptom [2] — the dose that leaves you able to return next session beats the dose that proves a point once.
  • Expect the questionnaire before the bloods. TSH moves little in the pairwise meta [4] while wellbeing, function and mental health move consistently [4][5][7][8] — judge the programme by energy, function and mood at your 8–12 week lab check, not by whether training "fixed" your TSH.
  • Log symptoms against training, not vibes. The hypothyroid week is noisy — cold, tired, poor sleep, cycle irregularities interact with training load exactly as they do in PCOS and menopause training. A logged programme turns "bad month" into a pattern you and your physician can read.
  • Know the red flags. New bradycardia, myxoedema features, pregnancy or planning it, chest pain on exertion — physician territory before any programming decision [2]. And if you're symptomatic on a normal TSH, that is a real, documented phenomenon [3][6] — worth a clinical conversation, not a bigger dose of self-prescribed cardio.
  • Don't out-train the weight-gain folklore. Hypothyroid weight gain is substantially water and reduced activity [2][10] — the fix is treatment plus a progressively moving baseline, not punishment cardio on a depleted gland.

How RightRep fits into this

The hypothyroid lifter's real problem is that the blood test is a quarterly snapshot while the adaptation is daily — and the fatigue, function and mood columns that training actually moves [4][5][8] are exactly the ones nobody measures between labs:

  • The fatigue-vs-load ledger gets built. "Tired all the time" is unactionable; sessions logged by load next to same-day energy notes is a correlation map — the pattern a tracked programme surfaces in weeks and hands your endocrinologist signal instead of anecdote.
  • The capacity column compounds visibly. The Brazilian file's functional-capacity repair [8] and the kinetics file's 10.7-second MRT gain [9] are precisely the increments a logged programme makes legible — progress the lab report will never show you.
  • The boring middle gets automated. The benefits in this file arrive at three sessions a week for 12–16 weeks [7][8][9] — the unglamorous consistency arc where a camera that counts your reps and a counter that never forgets a session earn their keep.
  • The two-modality programme gets enforced. The winning combination is aerobic plus resistance [5][7] — a programme page that schedules both is the difference between the preferred strategy and the usual one-modality drift.
  • The bad week gets caught early. Symptom flares, dose changes and cycle irregularities interact with training load — the log is where the interaction becomes visible before it becomes a setback.

The bottom line

Does exercise help hypothyroidism? Yes — for the person, honestly not much for the gland. The pill normalizes the blood while a substantial proportion of patients keep their complaints [2][3][6]; training is the reverse instrument — safe, and reliably improving the physical function, quality of life and mental health the pill leaves behind [4], with the 2026 network meta crowning levothyroxine + aerobic + resistance as the preferred add-on (TSH −3.97 high certainty, QoL +1.62, mental health +2.1 [5]) even as the pairwise meta keeps pooled TSH statistically flat (−0.96, CI −2.71 to 0.79 [4]) — the tension priced, both directions true. Every modality works, combined works best, aerobic wins the lungs [7]; the Brazilian file numbers the deficit (functional capacity 77.0 vs 88.8) and its 16-week repair [8]; the kinetics file speeds the heart 39.6 → 28.9 seconds [9]; and the population null keeps the mechanism honest — TSH doesn't even decide who moves [10]. Take the levothyroxine. Train anyway — combined, low-to-moderate to start, twelve to sixteen weeks before judging — and log the fatigue against the load until the questionnaire answers before the bloods do. That logging starts at rightrep.app, where the camera counts the rep and the log prices the adaptation the lab report hides.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology, 2018;14(5):301–316. pubmed.ncbi.nlm.nih.gov
  2. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. The Lancet, 2017;390(10101):1550–1562. pubmed.ncbi.nlm.nih.gov
  3. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clinical Endocrinology, 2002;57(5):577–585. pubmed.ncbi.nlm.nih.gov
  4. Duñabeitia I, González-Devesa D, Varela-Martínez S, Diz-Gómez JC, Ayán-Pérez C. Effect of physical exercise in people with hypothyroidism: systematic review and meta-analysis. Scandinavian Journal of Clinical and Laboratory Investigation, 2023;83(8):523–532. pubmed.ncbi.nlm.nih.gov
  5. Lv X, Qin W, Li J, Du L. Additional treatment strategies for hypothyroidism: a network meta-analysis. Endocrine Connections, 2026;15(4):e260011. pubmed.ncbi.nlm.nih.gov
  6. Thvilum M, Lind SM, Ebbehoj E, Gregersen S, Grove-Laugesen D. Quality of life in patients with overt hypothyroidism: a systematic review. European Journal of Endocrinology, 2025;193(3):S26–S35. pubmed.ncbi.nlm.nih.gov
  7. Ahmad AM, Serry ZH, Abd Elghaffar HA, Ghazi HA, El Gayar SL. Effects of aerobic, resistance, and combined training on thyroid function and quality of life in hypothyroidism. A randomized controlled trial. Complementary Therapies in Clinical Practice, 2023;53:101795. pubmed.ncbi.nlm.nih.gov
  8. Werneck FZ, Coelho EF, Almas SP, Garcia MMDN, Bonfante HLM, Lima JRP, Vigário PDS, Mainenti MRM, Teixeira PFDS, Vaisman M. Exercise training improves quality of life in women with subclinical hypothyroidism: a randomized clinical trial. Archives of Endocrinology and Metabolism, 2018;62(5):530–536. pubmed.ncbi.nlm.nih.gov
  9. Almas SP, Werneck FZ, Coelho EF, Teixeira PFS, Vaisman M. Endurance training improves heart rate on-kinetics in women with subclinical hypothyroidism: a preliminary study. Journal of Endocrinological Investigation, 2023;46(1):51–57. pubmed.ncbi.nlm.nih.gov
  10. Roa Dueñas OH, Koolhaas C, Voortman T, Franco OH, Ikram MA, Peeters RP, Chaker L. Thyroid function and physical activity: a population-based cohort study. Thyroid, 2021;31(6):870–875. pubmed.ncbi.nlm.nih.gov
  11. Bianco AC. Emerging therapies in hypothyroidism. Annual Review of Medicine, 2024;75:307–319. pubmed.ncbi.nlm.nih.gov
  12. Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, Mason J, Sattar N, McMurray JJV, McInnes IB, Khunti K, Cambridge G. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. The Lancet, 2023;401(10391):1878–1890. pubmed.ncbi.nlm.nih.gov